devinitorg/iati-policy-markers huggingface dataset:
ACCESS SMC [Africa Region] ACCESS SMC will implement Seasonal Malaria Chemoprevention (SMC)  at scale in seven countries in the Sahel, providing approximately 30 percent of total treatments needed for all eligible children per annum in years 2015 and 2016. In the continued fight against malaria in Africa, there is increased recognition of the need to tailor combinations of potential interventions to local needs.  It is in this context that seasonal malaria chemoprevention (SMC) has been approved by the World Health Organization (WHO) and has the potential to become an important tool in the prevention of malaria.  SMC, achieved by administering up to four monthly doses of sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), or SP+AQ, is applicable in areas with high seasonal variation in malaria transmission and where resistance to SP+AQ is low, with the greatest opportunity for impact being in the Sahel.  SMC is targeted at 23.7 million children aged three to 59 months who bear the greatest risk of mortality.  It is highly effective, and has the potential to prevent 75% of uncomplicated and severe malaria cases.  [Africa Region]
ACCESS SMC [Guinea] ACCESS SMC will implement Seasonal Malaria Chemoprevention (SMC)  at scale in seven countries in the Sahel, providing approximately 30 percent of total treatments needed for all eligible children per annum in years 2015 and 2016. In the continued fight against malaria in Africa, there is increased recognition of the need to tailor combinations of potential interventions to local needs.  It is in this context that seasonal malaria chemoprevention (SMC) has been approved by the World Health Organization (WHO) and has the potential to become an important tool in the prevention of malaria.  SMC, achieved by administering up to four monthly doses of sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), or SP+AQ, is applicable in areas with high seasonal variation in malaria transmission and where resistance to SP+AQ is low, with the greatest opportunity for impact being in the Sahel.  SMC is targeted at 23.7 million children aged three to 59 months who bear the greatest risk of mortality.  It is highly effective, and has the potential to prevent 75% of uncomplicated and severe malaria cases.
ACCESS SMC [Gambia] ACCESS SMC will implement Seasonal Malaria Chemoprevention (SMC)  at scale in seven countries in the Sahel, providing approximately 30 percent of total treatments needed for all eligible children per annum in years 2015 and 2016. In the continued fight against malaria in Africa, there is increased recognition of the need to tailor combinations of potential interventions to local needs.  It is in this context that seasonal malaria chemoprevention (SMC) has been approved by the World Health Organization (WHO) and has the potential to become an important tool in the prevention of malaria.  SMC, achieved by administering up to four monthly doses of sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), or SP+AQ, is applicable in areas with high seasonal variation in malaria transmission and where resistance to SP+AQ is low, with the greatest opportunity for impact being in the Sahel.  SMC is targeted at 23.7 million children aged three to 59 months who bear the greatest risk of mortality.  It is highly effective, and has the potential to prevent 75% of uncomplicated and severe malaria cases.  [Gambia] [Guinea]
ACCESS SMC [Mali] ACCESS SMC will implement Seasonal Malaria Chemoprevention (SMC)  at scale in seven countries in the Sahel, providing approximately 30 percent of total treatments needed for all eligible children per annum in years 2015 and 2016. In the continued fight against malaria in Africa, there is increased recognition of the need to tailor combinations of potential interventions to local needs.  It is in this context that seasonal malaria chemoprevention (SMC) has been approved by the World Health Organization (WHO) and has the potential to become an important tool in the prevention of malaria.  SMC, achieved by administering up to four monthly doses of sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), or SP+AQ, is applicable in areas with high seasonal variation in malaria transmission and where resistance to SP+AQ is low, with the greatest opportunity for impact being in the Sahel.  SMC is targeted at 23.7 million children aged three to 59 months who bear the greatest risk of mortality.  It is highly effective, and has the potential to prevent 75% of uncomplicated and severe malaria cases.  [Mali]
ACCESS SMC ACCESS SMC will implement Seasonal Malaria Chemoprevention (SMC)  at scale in seven countries in the Sahel, providing approximately 30 percent of total treatments needed for all eligible children per annum in years 2015 and 2016. In the continued fight against malaria in Africa, there is increased recognition of the need to tailor combinations of potential interventions to local needs.  It is in this context that seasonal malaria chemoprevention (SMC) has been approved by the World Health Organization (WHO) and has the potential to become an important tool in the prevention of malaria.  SMC, achieved by administering up to four monthly doses of sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), or SP+AQ, is applicable in areas with high seasonal variation in malaria transmission and where resistance to SP+AQ is low, with the greatest opportunity for impact being in the Sahel.  SMC is targeted at 23.7 million children aged three to 59 months who bear the greatest risk of mortality.  It is highly effective, and has the potential to prevent 75% of uncomplicated and severe malaria cases.
ACCESS SMC [Chad] ACCESS SMC will implement Seasonal Malaria Chemoprevention (SMC)  at scale in seven countries in the Sahel, providing approximately 30 percent of total treatments needed for all eligible children per annum in years 2015 and 2016. In the continued fight against malaria in Africa, there is increased recognition of the need to tailor combinations of potential interventions to local needs.  It is in this context that seasonal malaria chemoprevention (SMC) has been approved by the World Health Organization (WHO) and has the potential to become an important tool in the prevention of malaria.  SMC, achieved by administering up to four monthly doses of sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), or SP+AQ, is applicable in areas with high seasonal variation in malaria transmission and where resistance to SP+AQ is low, with the greatest opportunity for impact being in the Sahel.  SMC is targeted at 23.7 million children aged three to 59 months who bear the greatest risk of mortality.  It is highly effective, and has the potential to prevent 75% of uncomplicated and severe malaria cases.  [Chad]
ACCESS SMC [Senegal] ACCESS SMC will implement Seasonal Malaria Chemoprevention (SMC)  at scale in seven countries in the Sahel, providing approximately 30 percent of total treatments needed for all eligible children per annum in years 2015 and 2016. In the continued fight against malaria in Africa, there is increased recognition of the need to tailor combinations of potential interventions to local needs.  It is in this context that seasonal malaria chemoprevention (SMC) has been approved by the World Health Organization (WHO) and has the potential to become an important tool in the prevention of malaria.  SMC, achieved by administering up to four monthly doses of sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), or SP+AQ, is applicable in areas with high seasonal variation in malaria transmission and where resistance to SP+AQ is low, with the greatest opportunity for impact being in the Sahel.  SMC is targeted at 23.7 million children aged three to 59 months who bear the greatest risk of mortality.  It is highly effective, and has the potential to prevent 75% of uncomplicated and severe malaria cases.  [Senegal]
ACCESS SMC [Burkina Faso] ACCESS SMC will implement Seasonal Malaria Chemoprevention (SMC)  at scale in seven countries in the Sahel, providing approximately 30 percent of total treatments needed for all eligible children per annum in years 2015 and 2016. In the continued fight against malaria in Africa, there is increased recognition of the need to tailor combinations of potential interventions to local needs.  It is in this context that seasonal malaria chemoprevention (SMC) has been approved by the World Health Organization (WHO) and has the potential to become an important tool in the prevention of malaria.  SMC, achieved by administering up to four monthly doses of sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), or SP+AQ, is applicable in areas with high seasonal variation in malaria transmission and where resistance to SP+AQ is low, with the greatest opportunity for impact being in the Sahel.  SMC is targeted at 23.7 million children aged three to 59 months who bear the greatest risk of mortality.  It is highly effective, and has the potential to prevent 75% of uncomplicated and severe malaria cases.  [Burkina Faso]
ACCESS SMC [Nigeria] ACCESS SMC will implement Seasonal Malaria Chemoprevention (SMC)  at scale in seven countries in the Sahel, providing approximately 30 percent of total treatments needed for all eligible children per annum in years 2015 and 2016. In the continued fight against malaria in Africa, there is increased recognition of the need to tailor combinations of potential interventions to local needs.  It is in this context that seasonal malaria chemoprevention (SMC) has been approved by the World Health Organization (WHO) and has the potential to become an important tool in the prevention of malaria.  SMC, achieved by administering up to four monthly doses of sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), or SP+AQ, is applicable in areas with high seasonal variation in malaria transmission and where resistance to SP+AQ is low, with the greatest opportunity for impact being in the Sahel.  SMC is targeted at 23.7 million children aged three to 59 months who bear the greatest risk of mortality.  It is highly effective, and has the potential to prevent 75% of uncomplicated and severe malaria cases.  [Nigeria]
ACCESS SMC [Niger] ACCESS SMC will implement Seasonal Malaria Chemoprevention (SMC)  at scale in seven countries in the Sahel, providing approximately 30 percent of total treatments needed for all eligible children per annum in years 2015 and 2016. In the continued fight against malaria in Africa, there is increased recognition of the need to tailor combinations of potential interventions to local needs.  It is in this context that seasonal malaria chemoprevention (SMC) has been approved by the World Health Organization (WHO) and has the potential to become an important tool in the prevention of malaria.  SMC, achieved by administering up to four monthly doses of sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), or SP+AQ, is applicable in areas with high seasonal variation in malaria transmission and where resistance to SP+AQ is low, with the greatest opportunity for impact being in the Sahel.  SMC is targeted at 23.7 million children aged three to 59 months who bear the greatest risk of mortality.  It is highly effective, and has the potential to prevent 75% of uncomplicated and severe malaria cases.  [Niger]
Support for the Fight Against Malaria in the Mono and Couffo Departments Malaria is endemic in Benin.  It is a primary cause of sickness and death in the country is an obstacle to socio-economic development.  With a goal of reducing malaria-related sickness and death among pregnant women and children under the age of five in the Mono and Couffo regions, the program supported by this grant will extend the implementation of malaria control activities, by promoting the use of insecticide-treated bed nets through women’s groups and health facilities; and by increasing access to early diagnosis and treatment with artemisinin-based combination therapies.  In addition, the program aims increase awareness about malaria prevention and treatment.
Acceleration of access to services for the prevention of HIV infection, of care and treatment and for community support Benin is a country with a general HIV epidemic.  At the end of 2007, UNAIDS estimated HIV prevalence in adult population at 1.2 percent with a significant gender disparity of 1.5 percent among women and 0.8 among men.  These estimates did not consider the appearance of new determinants which favor the propagation of infection such as sex workers and their clients, men who have sex with men (MSM) and injecting drug users (IDUs).  The Program was developed based on the lessons learned from Round 2 and Round 5 of Global Fund grants and aims to ensure that objectives of the National Strategic Framework for the fight against AIDS are met by 2015.  It encompasses achieving universal access to the prevention, treatment, care and support of persons infected and affected by HIV, through strengthening health and community systems.  The Program consolidates Round 5 and Round 9 HIV grants and is implemented by three Principal Recipients.
Stepping up community malaria care for children under five in 14 health zones in Benin in an extended partnership with a view to increased impact Malaria is endemic in Benin. It is a primary cause of sickness and death in the country and is an obstacle to socioeconomic development. The program supported by this grant aims to reduce malaria-related sickness and death among children under age 5 by scaling up the number of community-based health zones from three to 14. The program, which builds on work done under a previous Global Fund grant will partner with community-based organizations to achieve the goal. The program will procure artemisinin-based combination therapy and organize the distribution of the treatment at the community level; train community workers and health agents in appropriate case management; and educate mothers and caregivers of children less than 5 years of age in the early and appropriate management of malaria symptoms.
Acceleration of access to services for the prevention of HIV infection, of care and treatment and for community support Benin - HIV - Programme santé de lutte contre le Sida - PSLS.  This program has the following goals: Contribuer à réduire de 50% d’ici 2023, les nouvelles infections liées aux pathologies prioritaires : VIH, tuberculose, paludisme, hépatites, IST, maladie à potentiel épidémique / Contribute to reducing by 50% new infections of HIV, tuberculosis, malaria, hepatitis, STIs, and illnesses with epidemic potential, by 2023.  Contribuer à  réduire de 60% d’ici 2023, la mortalité et la morbidité liées aux pathologies prioritaires : VIH, tuberculose, paludisme, hépatites, IST et maladies à potentiel épidémique ;/ Contribute to reducing by 60% mortality and morbidity linked to priority infections from HIV, tuberculosis, malaria, hepatitis, STIs, and illnesses with epidemic potential, by 2023.  Assurer une gouvernance intégrée et performante de la riposte nationale aux pathologies prioritaires et aux maladies à potentiel épidémique / Ensure integrated and effective governance of the response to priority diseases and illnesses with epidemic potential.. The objectives of this program are: Amener d''ici à 2023, 90% des professionnels de sexe, 90% des détenus  à utiliser le paquet de services de prévention combinée / Ensure that by 2023, 90% of female sex workers, 90% of prisonners, use the combined package of prevention services..  Maintenir à au moins 95% d'ici à 2023 la proportion de femmes enceintes séropositives utilisant les ARV pour réduire la TME / Maintain to at least 95% by 2023, the proportion of HIV-positive pregant women who use ARVs to reduce mother-to-child transmission..  Reduire à moins de 2% d'ici à 2023, la transmission du VIH de la mère à l’enfant / Reduce to at least 2% by 2023 the rate of mother-to-child transmission.  Porter à 82% le pourcentage des PVVIH adultes, adolescents et enfants recevant un traitement antirétroviral; à 90% le pourcentage des PVVIH (adultes, adolescents et enfants) ayant une charge virale indétectable à 12 mois/ Increase to 82% the percentage of adult, child and adolescents living with HIV who are receiving ART; and to 90% the percentage of PLHIV who have an undetectable viral load at 12 months.
Benin - HIV - United Nations Development Programme Benin - HIV - United Nations Development Programme - UNDP HQ.
Benin - Malaria - United Nations Development Programme Benin - Malaria - United Nations Development Programme - UNDP HQ.
Intensification of access to HIV services for key and vulnerable populations Benin - HIV - Plan International, Inc. - Plan HQ.  This program has the following goals: Réduire de 50% d’ici 2026, les nouvelles infections liées aux pathologies prioritaires : VIH, tuberculose, paludisme, hépatites, IST, maladie à potentiel épidémique// By 2026, reduce by 50% new infections related to priority diseases: HIV, tuberculosis, malaria, hepatitis, STIs, diseases with epidemic potential.  Réduire de 60% d’ici 2026, la mortalité et la morbidité liées aux pathologies prioritaires : VIH, tuberculose, paludisme, hépatites, IST et maladies à potentiel épidémique// By 2026, reduce mortality and morbidity related to priority diseases by 60% : HIV, tuberculosis, malaria, hepatitis, STIs and diseases with epidemic potential..  .  . The objectives of this program are: Assurer une couverture d'au moins 95 % d'ici 2030 de la population ciblée (HSH, TG, CDI) avec toutes les interventions de prévention pertinentes Ensure at least 95% coverage by 2030 of the target population (MSM, TG, UDI) with all relevant prevention interventions.  Renforcer les stratégies de dépistage différencié du VIH Strengthening differentiated HIV testing strategies.  Réduire les obstacles liés aux droits humains qui entravent l’accès aux services de lutte contre le VIH, la TB et le paludisme Reduce human rights barriers to accessing HIV, TB and malaria services.  .  .  .
HSS GRANT FOR BENIN Benin - RSSH - Health System Performance Program - HSPP.  This program has the following goals: By 2017, contribute to the achievement of the MDGs 4 (infant mortality), 5 (maternal mortality) and 6 (HIV, TB and malaria) through the strengthening of health systems. The objectives of this program are: Improve the allocative efficiciency of the health budget.  Strengthen the health system to ensure better coverage of health services.  Increase coverage of quality maternal, neonatal and children services, as well as preventive and treatment services for HIV, TB and malaria in the 19 health zones supported by the Global Fund
Benin - HIV - Ministry of Health of the Government of the Republic of Benin Benin - HIV - Ministry of Health of the Government of the Republic of Benin.
Benin - Tuberculosis - United Nations Development Programme Benin - Tuberculosis - United Nations Development Programme - UNDP HQ.
Building resilient and sustainable health systems in Benin to improve access and quality of health care Benin - RSSH - Conseil National de Lutte contre le VIH/SIDA, la Tuberculose, le Paludisme, les Hépatites, les Infections sexuellement transmissibles et les Epidémies - CNLS-TP.  This program has the following goals: Help improve public health by ensuring Benin has an effective, resilient health system.. The objectives of this program are: Improve human resources management at the operational and community levels..  Strengthen the National Health Management Information System (NHMIS) and the activity monitoring and evaluation (M&E) system to support informed decision-making..  Introduce an effective procurement and supply management (PSM) system for health supplies..  Expand national coverage of high-quality services and service delivery..  Strengthen institutional capacities and intervention coordination.
Strengthening the National Response to Tuberculosis in Benin Benin - Tuberculosis - National Tuberculosis Programme of the Republic of Benin - PNT.  This program has the following goals: Réduire de 50% d’ici 2023, les nouvelles infections liées aux pathologies prioritaires : VIH, tuberculose, paludisme, hépatites, IST, maladie à potentiel épidémique// By 2023, reduce by 50% new infections related to priority diseases: HIV, tuberculosis, malaria, hepatitis, STIs, diseases with epidemic potential.  Réduire de 60% d’ici 2023, la mortalité et la morbidité liées aux pathologies prioritaires : VIH, tuberculose, paludisme, hépatites, IST et maladies à potentiel épidémique// By 2023, reduce mortality and morbidity related to priority diseases by 60% : HIV, tuberculosis, malaria, hepatitis, STIs and diseases with epidemic potential..  Assurer une gouvernance intégrée et performante de la riposte nationale aux pathologies prioritaires et aux maladies à potentiel épidémique // Ensure integrated and efficient governance of the national response to priority pathologies and diseases with epidemic potential. The objectives of this program are: Le nombre de nouveaux cas de tuberculose toutes formes notifiées est augmenté de 24% en 2023 (4003 en 2018 à 4945 en 2023)//The number of newly notified cases of TB increases by 24% between 2018 and 2023(from 4003 in 2018 to 4945 in 2023)..  Le taux de succès thérapeutique chez les nouveaux cas de tuberculose toutes formes et rechutes est porté à 90% en 2023// Percentage of all forms of TB cases (bacteriologically confirmed plus clinically diagnosed) successfully treated (cured plus treatment completed) among all forms of TB cases registered for treatment reaches 90% by 2023.  Le taux de décès chez les patients Co-infectés TB/VIH est réduit à au plus 10% en 2023 // The mortality rate among co-infected TB/HIV patients is reduced to less than 10% by 2023.  Au moins 80% des malades multi-résistants mis sous traitement de 2ème ligne sont guéris en 2023 // At least 80% of patients with MDR-TB who are on treatment are cured, by 2023
Strengthening malaria control in Benin Benin - Malaria - Programme National de Lutte contre le Paludisme de la République du Bénin - PNLP.  This program has the following goals: Contribuer à l’amélioration de l’état de santé général de la population en réduisant de façon significative le fardeau du paludisme d’ici 2021. The objectives of this program are: D'ici 2021, réduire le taux d’incidence du paludisme d’au moins 40% par rapport à 2015.  D'ici 2021, réduire le taux de mortalité liée au paludisme d’au moins 40% par rapport à 2015.  Renforcer les capacités de gestions du programme à tous les niveaux
Benin - Tuberculosis - Ministry of Health of the Government of the Republic of Benin Benin - Tuberculosis - Ministry of Health of the Government of the Republic of Benin.
Erhöhung der Ernährungssouveränität und Aufbau von Vertrauen durch Austausch, Fortführung DPRK Development Assistance Program Förderung von 4 ausgesuchten landwirtschaftlichen Kooperativen mit dem Ziel der Diversifizierung und Produktionssteigerung der Tier- und v.a. Pflanzenproduktion.  Dies wird erreicht durch eine Verbesserung der Anbaumethoden und ein effizienteres Management.  Eine Komponente des Projekts beeinhaltet die Kapazitätsbildung durch Seminare, Trainings und Studienreisen ins Ausland. Facilitation and support of 4 selected cooperative farms with the objective of diversification and increase of crop and animal production.    This will be achieved through improvement of cultivation methods and a more efficient management.    One component of the project includes capacity building through seminars, trainings and study tours abroad. Förderung von 4 ausgesuchten landwirtschaftlichen Kooperativen mit dem Ziel der Diversifizierung und Produktionssteigerung der Tier- und v.a. Pflanzenproduktion.  Dies wird erreicht durch eine Verbesserung der Anbaumethoden und ein effizienteres Management.  Eine Komponente des Projekts beeinhaltet die Kapazitätsbildung durch Seminare, Trainings und Studienreisen ins Ausland. Facilitation and support of 4 selected cooperative farms with the objective of diversification and increase of crop and animal production.    This will be achieved through improvement of cultivation methods and a more efficient management.    One component of the project includes capacity building through seminars, trainings and study tours abroad.